Thyroid peroxidase antibodies and their role in predicting outcomes in Graves’ disease treatment
IntroductionGraves´ disease (GD) is the predominant cause of hyperthyroidism. Treatment options include antithyroid drugs (ATD), surgery, and radioactive iodine ablation (RI). Although thyroid peroxidase antibodies (anti-TPO) are prevalent in patients with GD, their role in driving relapse or hypoth...
Saved in:
| Main Authors: | Klara Gewert, Geriolda Topi, Tereza Planck, Jan Calissendorff |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1517283/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term outcomes of graves disease in children treated with anti-thyroid drugs
by: Ya-Ting Chiang, et al.
Published: (2020-06-01) -
Targeted immunotherapies for Graves’ thyroidal & orbital diseases
by: Alan Chun Hong Lee, et al.
Published: (2025-03-01) -
Characteristics of patients with Graves’ disease who developed drug resistance and required surgery
by: Yusuke Shibata, et al.
Published: (2025-04-01) -
Response: Commentary: Azathioprine as an adjuvant therapy in severe Graves’ disease: a randomized controlled open-label clinical trial
by: Magdy Mohamed Allam, et al.
Published: (2024-12-01) -
Comparing antithyroid drugs vs. radioactive iodine in paediatric Graves’ disease: literature review
by: Akshat Sinha, et al.
Published: (2025-05-01)